Radium-223 decreases PD-L1 expression in bone metastases: A study with [89Zr]Zr-atezolizumab PET and immunohistological correlation
European Journal of Nuclear Medicine and Molecular Imaging · 2026-11 · 53 (13) · 8558-8567
DOI: 10.1007/s00259-026-08175-9 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 12.09.2026. Verfasst von Sui Wai Ling und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, B7-H1 Antigen, Bone Neoplasms, Positron-Emission Tomography. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer, Foundation Dutch Uro-Oncology Study Group, Running Stairs for Cancer.
Abstract (Originalsprache)
Purpose
Most patients with metastatic castration-resistant prostate cancer (mCRPC) do not benefit from treatment with immune checkpoint inhibitors targeting programmed cell death (ligand) 1 (PD-(L)1). Radiation might improve response to immunotherapy by increasing the immunogenicity of prostate cancer. The objective of this study was to investigate radium-223-mediated changes in the micro- and macroenvironment of mCRPC.
Methods
In this prospective, multicenter study (ICTRP NL-OMON26890), 28 patients with mCRPC and predominantly bone metastases were treated with radium-223, according to standard-of-care. Primary endpoint was failure-free survival (FFS). Imaging included sequential positron emission tomography (PET) with gallium-68 prostate-specific membrane antigen ( 68 Ga-PSMA) and zirconium-89 atezolizumab ( 89 Zr-atezolizumab) to quantify whole-body expression of PD-L1 in vivo (SUV mean/max ). Paired PET analysis included nine patients. The immune status of patients was characterized in biopsies from bone metastases and in blood using (multiplex) immunohistochemistry (IHC) and flow cytometry, respectively. Sequential biopsy analysis included two patients.
Results
89 Zr-atezolizumab uptake in 68 Ga-PSMA positive bone metastases showed high intra- and inter-patient heterogeneity. In the total volume of 68 Ga-PSMA-positive bone lesions, the median SUV mean of 89 Zr-atezolizumab was 2.5 (IQR 0.9–3.4) at baseline and 0.9 (IQR 0.5–2.5) after three cycles of radium-223, which was higher than the physiological uptake in bone marrow at baseline and after treatment with radium-223. After three cycles of radium-223, 89 Zr-atezolizumab uptake decreased in bone metastases, independent of response on 68 Ga-PSMA PET, and the number of lymphocytes in tumor tissue and blood decreased concomitantly.
Conclusions
Treatment of mCRPC bone metastases with radium-223 results in a significant decrease of in vivo PD-L1-expression on PET imaging and a decrease in immune cells in bone metastases and blood. These findings indicate that treatment with alpha emitting radium-223 alters the immune microenvironment, thereby potentially reducing the efficacy of PD-(L)1 inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands.
- Department of Medical Oncology, Erasmus MC Cancer Institute, Doctor Molewaterplein 40 3015 GD, Rotterdam, the Netherlands.
- Department of Medical BioSciences, Radboudumc, Nijmegen, the Netherlands.
- Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands.
- Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
- Department of Clinical Pharmacy and Pharmacology, UMC Groningen, University of Groningen, Groningen, the Netherlands.
Förderung
- Bayer
- Foundation Dutch Uro-Oncology Study Group
- Running Stairs for Cancer
Zitieren
APA
Ling, S. W., de Jong, A., Gorris, M., Segbers, M., Graven, L., van Driel, M., van Leenders, G., Isebia, K., de Hooge, M. L., Hamberg, P., Mehra, N., van Brakel, M., de Wit, R., Debets, R., de Vries, E., Brabander, T., de Vries, J., & van der Veldt, A. (2026). Radium-223 decreases PD-L1 expression in bone metastases: A study with [89Zr]Zr-atezolizumab PET and immunohistological correlation. European Journal of Nuclear Medicine and Molecular Imaging, 53(13), 8558-8567. https://doi.org/10.1007/s00259-026-08175-9
Vancouver
Ling SW, de Jong A, Gorris M, Segbers M, Graven L, van Driel M, et al. Radium-223 decreases PD-L1 expression in bone metastases: A study with [89Zr]Zr-atezolizumab PET and immunohistological correlation. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(13):8558-8567. doi:10.1007/s00259-026-08175-9
BibTeX
@article{Ling2026,
author = {Ling, Sui Wai and de Jong, Anouk and Gorris, Mark and Segbers, Marcel and Graven, Laura and van Driel, Marjolein and van Leenders, Geert and Isebia, Khrystany and de Hooge, Marjolijn Lub- and Hamberg, Paul and Mehra, Niven and van Brakel, Mandy and de Wit, Ronald and Debets, Reno and de Vries, Elisabeth and Brabander, Tessa and de Vries, Jolanda and van der Veldt, Astrid},
title = {Radium-223 decreases PD-L1 expression in bone metastases: A study with [89Zr]Zr-atezolizumab PET and immunohistological correlation},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
volume = {53},
number = {13},
pages = {8558--8567},
doi = {10.1007/s00259-026-08175-9}
}
EUVIMED